Loerop James 4
4 · Aclaris Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Loerop James
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-31+73,750→ 177,056 total - Tax Payment
Common Stock
2025-12-31$3.01/sh−33,994$102,322→ 143,062 total - Exercise/Conversion
Common Stock
2026-01-02+18,150→ 161,212 total - Tax Payment
Common Stock
2026-01-02$2.88/sh−6,171$17,772→ 155,041 total - Exercise/Conversion
Restricted Stock Units
2025-12-31−73,750→ 0 total→ Common Stock (73,750 underlying) - Exercise/Conversion
Restricted Stock Units
2026-01-02−18,150→ 18,700 total→ Common Stock (18,150 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025.
- [F4]The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.